Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: PR Newswire
NetworkNewsWire Editorial CoverageNEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.'s (OTCQB: OTLC) (profile) Deciparticle(TM) platform exemplifies this shift. It offers a novel approach to increase the bioavailability and therapeutic index of existing cancer drugs, potentially transforming underperforming compounds into next-generation therapies. The recent advancement of Sapu-003 into human trials signals rea
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025GlobeNewswire
- Bicara Therapeutics (NASDAQ:BCAX) had its price target raised by analysts at Wells Fargo & Company from $8.00 to $11.00. They now have an "equal weight" rating on the stock.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.MarketBeat
- Bicara Therapeutics GAAP EPS of -$0.67 [Seeking Alpha]Seeking Alpha
- Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
BCAX
Earnings
- 11/10/25 - Miss
BCAX
Sec Filings
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B5
- 11/25/25 - Form 4
- BCAX's page on the SEC website